Director:
Vascular and Endovascular Sciences
Vice President:
Vascular Access Society of India
Editorial Board:
Annals of Vascular Surgery
Councilor:
Asian Society of Vascular Surgery
2009 - Invited to present paper at the World Federation of Vascular Societies in Oslo, Norway
2008 - Presented paper at the Annual Congress of European Society of Vascular Surgeons at Nice, France
Daiichi-Sankyo ”HOKUSAI” Protocol DU176b-D-U305
March 2010 – March 2010
Investigator Meeting
Team members:
Dr Tarun Grover
FOX HOLLOW intra luminal atherectomy device FHT-P-06-003
September 2007 – September 2007
Investigator Meeting, Plaque removal verses open bypass surgery in critical limb ischemia. Bangalore.
Team members:
Dr Tarun Grover
Handbook of Vascular Surgery
2004 – 2004
Raynaud’s Syndrome, Vascular Society of India
Team members:
Dr Tarun Grover
EINSTEIN MAIN (11702)
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic DVT or PE.
Team members:
Dr Tarun Grover
ASPIRE (CTC 0005)
Aspirin To Prevent Recurrent VTE
Team members:
Dr Tarun Grover
Approach to Endovascular Interventions
Co-editor. EVL 2018
Team members:
Dr Tarun Grover
DFU (CLINIGENE) ) (HO-09-01)
Safety & efficacy of HO/03/03 10 µg in the treatment of Plantar Neuropathic diabetic foot ulcers
Team members:
Dr Tarun Grover
LIFENOX (ENOXA_C_01249)
International, multicenter, randomized, double blind study to compare the overall mortality in acutely ill medical patients treated with enoxaparin versus Placebo in addition to Graduated elastic stockings.
Team members:
Dr Tarun Grover
PPD (185056 and 185057)
A safety & efficacy trial evaluating the use of Apixaban for the extended treatment of DVT & PE.
Team members:
Dr Tarun Grover
RECOVER II 1160.46
A phase III randomized, double blind, parallelgroup study of the efficacy and safety of oral dabigatran etexilate(150 mg bid) compared to warfarin(INR 2.0-3.0) for 6 months treatment of acute symptomatic venous thromboembolism, following initial treatment for at least 5 days with a parenteral anticoagulant approved for this indication.
Team members:
Dr Tarun Grover
Vascular Diseases Simplified
Thoracic Outlet Syndrome. JAYPEE Publication
Team members:
Dr Tarun Grover
“EU-CORE” European CUBICIN CCBC13412403
Outcome registry and experience for the treatment of serious gram positive infections
Team members:
Dr Tarun Grover
Daiichi-Sankyo”HOKUSAI” Protocol DU176b-D-U305
January 2010 – January 2010
Investigator Meeting, Sydney
Team members:
Dr Tarun Grover
Annual Vascular Updates
2004 – 2004
Thoracic Outlet Syndrome. Army R & R Hospital
Team members:
Dr Tarun Grover
Handbook of Vascular Surgery
2001 – 2001
Acute limb Ischemia. VSICON 2001.
Team members:
Dr Tarun Grover
STEMPEUTICS MANIPAL ACCUNOVA SRPL/CLI/07-08/001
A randomized double blind multiocentric, placebo controlled single dose, phase-I/II study assessing the safety and efficacy of intramuscular Ex vivo cultured adult allogenic mesenchymal stem cells in patients with CLI.
Team members:
Dr Tarun Grover
Approach to Endovascular Interventions
Co-Editor of the Book
Team members:
Dr Tarun Grover
DBT CLI
Safety & efficacy of auto-logous stem cells in prevention of amputation in patients with chronic CLI
Team members:
Dr Tarun Grover
EINSTEIN EXTN (11899)
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic DVT or PE.
Team members:
Dr Tarun Grover
National Lead Investigator
Team for Edoxaban: DU176b-D-U305 (HOKUSAI-VTE Program)
Team members:
Dr Tarun Grover
RECOVER 1160.53
A phase III, randomized, double blind, parallelgroup study of the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for 6 month treatment of acute symptomatic venous thromboembolism, following initial treatment (5-10 days) with a parenteral anticoagulant approved for this indication secondary prevention of venous thromboembolism.
Team members:
Dr Tarun Grover
REMEDY 1160.47
A phase III, randomized, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) compared to warfarin (INR 2.0-3.0) for the secondary prevention of venous thromboembolism
Team members:
Dr Tarun Grover
Venous Disorder Current Concept
Sclerotherapy for varicose vein facts and myths. SPRINGER
Team members:
Dr Tarun Grover
CH Baktawar Singh Road, Sector 38, Gurugram, Haryana 122001
